IA2 Insulin Autoantibodies

Diabetes

Report in 168Hrs

At Home

No Fasting Required

Details

Detects autoantibodies against pancreatic islets.

₹2,960₹4,229

30% OFF

IA2 Insulin Autoantibodies - Comprehensive Medical Test Guide

Why is it done?
- What the test measures: The IA2 (Islet Antigen-2) Insulin Autoantibodies test detects autoantibodies against the IA2 protein, an enzyme found on the surface of pancreatic beta cells. This test identifies one of the key autoimmune markers associated with Type 1 diabetes mellitus.
- Primary indications for ordering: Screening for Type 1 diabetes in individuals with symptoms or family history; Differentiating Type 1 diabetes from Type 2 diabetes; Identifying at-risk individuals in relatives of Type 1 diabetes patients; Predicting the progression from prediabetic state to overt Type 1 diabetes; Monitoring disease progression in newly diagnosed Type 1 diabetes patients
- Typical timing and circumstances: Performed when Type 1 diabetes is suspected based on clinical presentation (polyuria, polydipsia, weight loss, fatigue); During routine screening in high-risk populations; When family history of autoimmune diabetes is present; As part of autoimmune antibody panels in newly diagnosed diabetic patients; In longitudinal studies monitoring progression of autoimmune beta cell destruction
Normal Range
- Reference ranges: Negative/Normal: <0.4 IU/mL (International Units per milliliter) or <0.4 mIU/L (milli-International Units per liter); Borderline: 0.4-0.9 IU/mL; Positive: ≥1.0 IU/mL (Note: Reference ranges may vary slightly between laboratories; always refer to the specific laboratory's reference values)
- Units of measurement: IU/mL (International Units per milliliter) or mIU/L (milli-International Units per liter); Some laboratories may report as a titer or ratio
- Interpretation of normal vs abnormal: Negative result: Indicates absence of IA2 autoantibodies; suggests low likelihood of Type 1 diabetes or autoimmune beta cell destruction; however, does not completely exclude Type 1 diabetes as other autoimmune markers may be present; Borderline result: Warrants repeat testing and clinical correlation; may indicate early autoimmune process or lab assay variability; Positive result: Indicates presence of IA2 autoantibodies; strongly suggestive of Type 1 diabetes or ongoing autoimmune beta cell destruction; correlates with increased risk of developing overt diabetes
- Clinical significance: Normal/Negative: Reduces probability of Type 1 diabetes; suggests diabetes may be Type 2 or other form; provides reassurance in at-risk relatives; Abnormal/Positive: Confirms autoimmune basis of diabetes; indicates need for appropriate management and monitoring; predicts need for insulin therapy; helpful for genetic counseling in families
Interpretation
- Single positive IA2 result: Indicates autoimmune beta cell destruction; associated with increased risk of Type 1 diabetes development; approximately 50-80% of patients with single IA2 positivity will develop Type 1 diabetes; more clinically significant when combined with other autoimmune markers
- Multiple positive autoantibodies: When IA2 is positive along with GAD65 (glutamic acid decarboxylase) and/or ZnT8 autoantibodies: >95% predictive value for Type 1 diabetes development; indicates rapid beta cell destruction; highest risk for progression to overt diabetes
- High-titer positive results: Results significantly above cutoff (>2-3 times the upper limit of normal) indicate more active autoimmune process; associated with faster progression to overt diabetes; may suggest earlier intervention consideration
- Negative IA2 in diagnosed Type 1 diabetes: Approximately 10-15% of Type 1 diabetes patients are seronegative for all measured autoimmune markers; may have autoimmune diabetes with antibodies against other beta cell antigens not routinely tested; indicates LADA (Latent Autoimmune Diabetes in Adults) if late presentation
- Factors affecting interpretation: Laboratory assay variation (different methods have different sensitivities); Time from symptom onset (antibody levels may fluctuate); Age at testing (children more likely to have multiple markers); Previous immunosuppressive therapy; Specimen handling and storage conditions; Presence of other autoimmune conditions
- Clinical significance of result patterns: IA2 positive + symptoms of hyperglycemia = Diagnostic of Type 1 diabetes; IA2 positive + normal glucose = At-risk individual requiring monitoring and follow-up; IA2 positive + family history = Heightened risk requiring lifestyle modifications and regular screening; Rising titers on serial testing = Accelerated beta cell destruction; Declining titers = May indicate ongoing autoimmune process with advanced beta cell loss
Associated Organs
- Primary organ systems involved: Endocrine system: Specifically the pancreas, particularly the islets of Langerhans and beta cells; Immune system: T cells and B cells targeting beta cell antigens; Metabolic system: Glucose homeostasis and energy metabolism
- Primary conditions diagnosed or monitored: Type 1 Diabetes Mellitus: The primary condition; characterized by autoimmune destruction of insulin-producing beta cells; LADA (Latent Autoimmune Diabetes in Adults): Slower-onset Type 1 diabetes in adults; Neonatal diabetes: Can present with autoimmune markers; Type 1 diabetes in remission (honeymoon phase): May show persistent autoantibodies
- Associated autoimmune conditions: Thyroid autoimmune disease (Graves' disease, Hashimoto's thyroiditis); Celiac disease (gluten-sensitive enteropathy); Addison's disease (adrenal insufficiency); Systemic lupus erythematosus (SLE); Rheumatoid arthritis; Vitiligo; Pernicious anemia
- Potential complications of Type 1 diabetes: Acute: Diabetic ketoacidosis (DKA), hypoglycemia, hyperglycemic hyperosmolar state; Chronic microvascular: Diabetic retinopathy (eye damage), diabetic nephropathy (kidney disease), diabetic neuropathy (nerve damage); Chronic macrovascular: Coronary artery disease, cerebrovascular disease, peripheral vascular disease; Other: Cardiovascular disease, hypertension, dyslipidemia, premature mortality
- Organ systems affected by chronic hyperglycemia: Eyes: Retinal damage leading to vision loss or blindness; Kidneys: Progressive renal failure requiring dialysis or transplantation; Nervous system: Peripheral nerve damage causing pain, numbness, or loss of sensation; Heart and blood vessels: Increased atherosclerosis and cardiovascular events; Skin and immune function: Impaired wound healing and increased infection risk
Follow-up Tests
- Complementary autoimmune antibody testing: GAD65 (Glutamic Acid Decarboxylase 65 antibodies); ZnT8 (Zinc Transporter 8 autoantibodies); ICA (Islet Cell Autoantibodies); IAA (Insulin Autoantibodies); Combined testing dramatically improves predictive value for Type 1 diabetes diagnosis and risk stratification
- Glucose metabolism testing: Fasting blood glucose; Oral glucose tolerance test (OGTT) with 2-hour glucose measurement; HbA1c (glycated hemoglobin) to assess long-term glucose control; Continuous glucose monitoring (CGM) for real-time glucose trends
- Metabolic function assessment: C-peptide levels (indicates residual beta cell function); Insulin levels; Proinsulin levels; These help assess degree of beta cell preservation
- Screening for associated autoimmune conditions: Thyroid peroxidase (TPO) and thyroglobulin antibodies; Tissue transglutaminase (tTG) IgA for celiac disease; Adrenal and parietal cell antibodies; These are recommended in newly diagnosed Type 1 diabetes patients
- Monitoring for diabetes complications: Urinalysis and urine albumin-to-creatinine ratio (UACR) for kidney disease screening; Lipid panel (total cholesterol, LDL, HDL, triglycerides); Blood pressure monitoring; Eye examination including dilated retinal exam; Nerve function testing (monofilament test, vibration testing); Baseline assessment within 5 years of diagnosis
- Monitoring frequency recommendations: HbA1c: Every 3 months if not at goal, every 6 months if stable; Fasting glucose: Every 3-6 months; Lipid panel: At diagnosis, then annually or as clinically indicated; Kidney function (creatinine, eGFR): Annually; Urine albumin: At diagnosis, then annually; Eye exams: Annually once diagnosis confirmed; At-risk relatives: Consider screening every 1-2 years or when clinical symptoms appear
- Serial IA2 testing: May be performed in research settings or high-risk individuals; Repeat testing 6-12 months after initial positive result; Useful in relatives of Type 1 diabetes patients for risk stratification; Serial measurements help predict progression timeline to overt diabetes
Fasting Required?
- Fasting requirement: NO - Fasting is NOT required for IA2 insulin autoantibody testing. The test measures antibody levels, which are not affected by food intake or recent meals.
- Patient preparation: No special fasting requirements; Can be drawn at any time of day; No dietary restrictions necessary; Can eat and drink normally before blood draw; Can take regular medications as prescribed
- Specimen collection requirements: Blood draw via venipuncture (typically 3-5 mL); Serum separator tube (SST) or similar collection tube as specified by the laboratory; Allow blood to clot at room temperature for 30 minutes; Centrifuge to separate serum; Proper labeling with patient identification
- Sample handling and storage: Store at room temperature until processing if processed same day; Refrigerate at 2-8°C if delayed processing (within 24-48 hours); For longer storage, freeze at -20°C or -70°C; Avoid repeated freeze-thaw cycles; Transport to laboratory promptly with appropriate precautions
- Medications and substances - no restrictions: Continue all regular medications including diabetes medications, antithyroid drugs, and other therapies; Antibody test results are not affected by medication use; No need to discontinue any medications before testing; Inform laboratory of any recent immunosuppressive therapy or biologics (for interpretation context only)
- Timing considerations: Can be performed at any time of day; No specific time-of-day restrictions; Results are stable and not subject to circadian variation like some hormonal tests; Can be combined with other fasting tests if needed (e.g., glucose tolerance test or lipid panel requiring fasting)

How our test process works!